Article: NPS Pharmaceuticals Pulls Out of Deal to Merge with Biotech Firm Enzon.

By Bob Mims, The Salt Lake Tribune Knight Ridder/Tribune Business News

Jun. 6--Just weeks away from a final shareholders vote, NPS Pharmaceuticals Inc. has pulled out of its controversial $1.6 billion merger with an unexpectedly struggling Enzon Pharmaceuticals.

Wall Street resoundingly praised the decision to abort the marriage. NPS shares soared 22 percent in trading Thursday on the Nasdaq Stock Market to $28.96, a $5.21 bump, while Enzon stock tumbled 70 cents, or 5 percent, to $14.30 per share.

The merger termination was "terrific news for NPS," said Adam Walsh, an analyst with Jefferies & Co.

"The strategic rationale behind ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!